22q11.2 Deletion Syndrome (DiGeorge): Heart Defects, Immunity, and Cognitive Effects

Think about a newborn arriving in the world with a heart that does not beat quite right, a thymus gland too small to build a proper immune defence, a calcium system out of balance, and a palate that did not form completely. Later, as the child grows, learning difficulties emerge, and by adolescence, psychiatric symptoms may appear. Each of these problems seems unrelated at first glance. But in many children, they share a single hidden cause — a tiny missing piece of chromosome 22. This is 22q11.2 Deletion Syndrome, one of the most common and complex chromosomal disorders in the world.

What Is 22q11.2 Deletion Syndrome?

22q11.2 Deletion Syndrome is the most common microdeletion syndrome. Its clinical presentation varies and it may present several medical complications, namely heart defects, cleft palate, autoimmune diseases, delayed development, and psychiatric disorders. Blue Cross NC

The condition was originally described under several different names — DiGeorge Syndrome, Velocardiofacial Syndrome, and CATCH 22, among others. All of these were eventually found to share the same underlying genetic cause. Today, the preferred medical term is 22q11.2 Deletion Syndrome, though DiGeorge Syndrome remains widely used.

22q11.2 Deletion Syndrome affects about 1 in 2,150 individuals, causing complex and variably penetrant clinical problems. This makes it one of the most frequently occurring chromosomal deletion syndromes, second only to Down Syndrome in prevalence. Cleveland Clinic

What Causes It?

Every human has 46 chromosomes arranged in 23 pairs. Chromosome 22 is one of the smaller ones. In people with this syndrome, a tiny segment from the long arm of chromosome 22 — at a specific location called 22q11.2 — is missing. The term “22q11.2” gives the specific location on the chromosome where genes are missing — from segment 11 on the long arm, called the q arm, of chromosome 22. When genes are missing, the body does not have the instructions it needs to develop as expected. Cincinnati Children’s

The missing segment contains around 30 to 40 genes. Among the most important is TBX1, a gene responsible for directing the development of the heart, thymus, parathyroid glands, and face. Many of the manifestations of the syndrome have been linked to deletion of the TBX1 gene on chromosome 22q11, which plays a role in neural crest cell migration, pharyngeal arch development, and formation of the pharyngeal pouches, leading to craniofacial defects and abnormal neural crest cell migration and survival. PubMed

Most cases occur spontaneously, with no family history. However, because the condition is autosomal dominant, an affected parent has a 50% chance of passing it to each child.

Heart Defects: The Most Visible Feature

The first sign that leads many families to a 22q11.2 diagnosis is a congenital heart defect detected shortly after birth. 22q11.2 Deletion Syndrome is often diagnosed because an infant is found to have a congenital heart defect such as Tetralogy of Fallot, interrupted aortic arch, truncus arteriosus, or ventricular septal defect. ScienceDirect

These are serious structural abnormalities in the heart and its major blood vessels. Tetralogy of Fallot, for example, involves four separate heart defects occurring together, causing oxygen-depleted blood to circulate around the body. Many of these heart defects require surgical correction in the first weeks or months of life. The success of modern cardiac surgery means that most affected children survive and go on to live with other aspects of the syndrome requiring management.

The Immune System: A Thymus Under Threat

The thymus gland, located behind the breastbone, is the organ where T cells — the soldiers of the immune system — are trained. In 22q11.2 Deletion Syndrome, this gland is frequently underdeveloped or absent. Thymic hypoplasia affects about 60 to 70% of patients, leading to T cell lymphopenias of varying severity. Cleveland Clinic

If the thymus size is small, infants may have lower T cell numbers than normal, making them vulnerable to recurrent infections. The most severe forms of DiGeorge Syndrome include a completely absent thymus, leading to very few T cells and an almost non-functional immune system. PubMed

Beyond infection risk, the immune dysfunction in 22q11.2 Deletion Syndrome also increases the likelihood of autoimmune conditions, where the immune system mistakenly attacks the body’s own tissues. Small or absent parathyroid glands, which sit near the thyroid and regulate calcium in the blood, can also cause dangerously low calcium levels — a condition called hypocalcaemia — that can trigger seizures in newborns if not treated promptly.

Cognitive and Developmental Effects

22q11.2 Deletion Syndrome encompasses a wide range of congenital, immunologic, developmental, and psychiatric manifestations resulting from disrupted pharyngeal arch development. These include learning disabilities and a markedly elevated risk of schizophrenia spectrum disorders. Wikipedia

Most children with the syndrome have some degree of intellectual difference. Learning disabilities — particularly in mathematics, reading, and abstract reasoning — are common. Speech and language delays appear early and often require intensive therapy. Many children also meet criteria for ADHD or anxiety disorders.

Individuals with 22q11.2 Deletion Syndrome are at increased risk for psychiatric disorders throughout development, especially autism spectrum disorders, attention-deficit/hyperactivity disorder, anxiety and affective disorders, and schizophrenia spectrum disorders and psychosis. NCBI

The schizophrenia risk is particularly striking. One third of all patients with 22q11.2 Deletion Syndrome develop schizophrenia-like symptoms. The prevalence of the deletion in patients with schizophrenia is 1 to 2%, making it one of the major known genetic risk factors for schizophrenia. This has made the syndrome an important area of psychiatric genetics research. Peak occurrence of psychosis risk was found during adolescence, with 62% of those aged 12 to 17 years showing significant psychiatric symptoms. Medscapenih

How Is It Diagnosed?

Diagnosis begins with clinical suspicion, often triggered by a heart defect at birth or by the pattern of multiple seemingly unrelated health issues. In the early 1990s, fluorescent in situ hybridisation — known as FISH — studies enabled the specific identification of 22q11.2 microdeletions that were found to underlie the heterogeneous group of patients previously diagnosed with DiGeorge or Velocardiofacial Syndrome. NCBI

Today, chromosomal microarray testing is the preferred diagnostic method and can detect the deletion with very high accuracy. Prenatal diagnosis is possible through amniocentesis or chorionic villus sampling when there is a family history or suspicious prenatal ultrasound findings. Once a child is found to have 22q11.2 Deletion Syndrome, it is recommended that all parents be tested to determine if they or their other children are at risk, since affected parents or siblings may not have obvious symptoms. PubMed

For more information on rare chromosomal conditions and global health resources, visit the World Health Organization and ObserverVoice.com.

How Is It Managed?

There is no cure for 22q11.2 Deletion Syndrome, but each of its many features can be addressed individually. Since 22q11.2 Deletion Syndrome has the ability to affect every system of the body, it is important that affected children are treated by a team of paediatric specialists who can identify the variety of physical and psychosocial needs these patients may have. The earlier these symptoms are detected, the more can be done to help. NORD

Cardiac surgery addresses heart defects in infancy. Calcium supplements manage hypocalcaemia. Immune monitoring guides decisions about vaccinations, infections, and, in severe cases, thymus transplantation or stem cell therapy. Speech therapy, occupational therapy, and special educational support are cornerstones of developmental care. Patients diagnosed with 22q11.2 Deletion Syndrome are at high risk for psychosis and should receive a multidisciplinary approach so that diagnosis and treatment are established as early as possible. Blue Cross NC

Psychiatric monitoring throughout adolescence is considered essential, with early intervention at the first signs of psychosis significantly improving long-term outcomes.

Frequently Asked Questions

Q1. Is 22q11.2 Deletion Syndrome hereditary? In most cases — around 90% — the deletion occurs spontaneously and is not inherited from a parent. However, if a parent carries the deletion, there is a 50% chance with each pregnancy of passing it on. All parents of an affected child should be offered genetic testing.

Q2. Can 22q11.2 Deletion Syndrome be detected during pregnancy? Yes. Prenatal testing options include chromosomal microarray analysis through amniocentesis or chorionic villus sampling. In some cases, foetal ultrasound may detect heart defects or other structural abnormalities that prompt genetic testing.

Q3. How does 22q11.2 Deletion Syndrome affect a child’s schooling? Most children benefit from individualised education plans that address learning disabilities in mathematics and language, speech therapy, and support for attention and anxiety. With early intervention and appropriate support, many children make strong academic progress.

Q4. What is the connection between 22q11.2 Deletion Syndrome and schizophrenia? The deletion is one of the strongest known single genetic risk factors for schizophrenia. About one in three to four individuals with the syndrome develops schizophrenia or related psychotic disorders, typically in adolescence or early adulthood. Psychiatric monitoring throughout this period is strongly recommended.

Q5. Can adults have 22q11.2 Deletion Syndrome without knowing? Yes. People with very mild features — such as a minor learning disability or slightly unusual facial features — may not receive a diagnosis until adulthood, sometimes only when a child is diagnosed and parents are tested. Psychiatric symptoms in adulthood occasionally lead to a first diagnosis.

References

1. National Organization for Rare Disorders — 22q11.2 Deletion Syndrome
2. Cleveland Clinic — DiGeorge Syndrome (22q11.2 Deletion Syndrome)
3. StatPearls / NIH — DiGeorge Syndrome
4. Immune Deficiency Foundation — DiGeorge or 22q11.2 Deletion Syndrome
5. PMC / NIH — The Systemic Effects of 22q11.2 Deletion Syndrome on Immunity
6. WHO — Rare Diseases Fact Sheet

Disclaimer

This article adapts publicly available information from WHO’s Rare Diseases page and other publicly available sources on 22q11.2 Deletion Syndrome, DiGeorge Syndrome, and chromosomal microdeletion disorders. This content is for informational and educational purposes only and does not constitute medical advice. Diagnosis and management of 22q11.2 Deletion Syndrome should always be guided by a qualified medical genetics team and multidisciplinary paediatric specialists. ObserverVoice.com is a news and information platform — not a healthcare provider.